The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas
- 1 July 2000
- journal article
- case report
- Published by Wiley in Clinical Endocrinology
- Vol. 53 (1) , 53-60
Abstract
OBJECTIVE To compare effectiveness and tolerability of quinagolide (CV 205–502) and cabergoline (CAB) treatments in 39 patients with prolactinoma. STUDY DESIGN All 39 patients were treated first w...Keywords
This publication has 29 references indexed in Scilit:
- Long-Term and Low-Dose Treatment with Cabergoline Induces Macroprolactinoma ShrinkageThe Journal of Clinical Endocrinology & Metabolism, 1997
- Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergolineThe Journal of Clinical Endocrinology & Metabolism, 1996
- Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptineClinical Endocrinology, 1994
- Dose‐dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre studyClinical Endocrinology, 1992
- Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptineThe Journal of Clinical Endocrinology & Metabolism, 1992
- Should dopamine agonist treatment for prolactinomas be life-long?Clinical Endocrinology, 1991
- Low Doses of Dopamine Agonists in the Long-Term Treatment of MacroprolactinomasNew England Journal of Medicine, 1985
- Bromocriptine-induced removal of endoplasmic membranes from prolactinoma cellsCellular and Molecular Life Sciences, 1985
- COMPARISON OF THE CLINICAL ACTIVITY OF MESULERGINE AND PERGOLIDE IN THE TREATMENT OF HYPERPROLACTINAEMIAClinical Endocrinology, 1985
- Effects of oestrogen and bromocryptine on in vivo secretion and mitosis in prolactin cellsNature, 1975